Females of childbearing potential must agree to continue acceptable birth control measures (example (eg): abstinence, surgically sterile male partner, stable oral contraceptives, or double-barrier ...

for orodispersible use versus oral budesonide viscous suspension (BVS) 2×5 mL/day (0.4 mg/mL) for short-term induction treatment of active EoE. Histological remission occurred in 100%, 94.7%, 94.7% ...

Budesonide oral suspension is the first approved swallowed corticosteroid for use in EoE by the United States (US) Food and Drug Administration (FDA). This phase 3 multicenter, randomized, ...

Background—The use of corticosteroids in active Crohn’s disease often becomes limited by side effects. Budesonide is a potent corticosteroid with low systemic bioavailability due to an extensive first ...

Shire said the US Food and Drug Administration granted the designation for SHP621 (budesonide oral suspension or BOS) for eosinophilic oesophagitis (EoE), an inflammatory condition of the ...

Current treatment guidelines for CID include the use of loperamide and octreotide but do not account for other therapies, including budesonide. Small case reports have shown benefit with budesonide in ...

The US regulator has cleared Eohilia (formerly TAK-721), an oral suspension formulation of the well-established steroid drug budesonide, for people 11 years and older with EoE after turning down ...